Search
for
Sort by
Research 151–180 of 771
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
- S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
- Upadacitinib for the treatment of alopecia areata – A case report
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Advances in the mechanism and new therapies of alopecia areata
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Citrullination at the Inflammatory Skin Barrier
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Spotlight in Plastic Surgery: October 2022
- 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Tofacitinib citrate alleviates alopecia universalis symptoms in recent case study
- Real-world Burden of Disease and Clinical Characteristics of Alopecia Areata Among Adults in Brazil: Results from a Cross-sectional Survey
- Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies
- Dual Relief: How Atopic Dermatitis Treatments Affect Alopecia Areata—A Small Retrospective Cohort Study
- A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
- Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
- Overview of alopecia areata for managed care and payer stakeholders in the United States